Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst commented, "We increasingly see ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE